Seoul National University Hospital Launches Syapse Platform, Hosts Symposium


By Andreas Heid


A little over a week ago, we celebrated the first launch of our precision medicine platform outside of the U.S. at Seoul National University Hospital (SNUH), a leading hospital in South Korea. SNUH hosted a symposium to celebrate the implementation, and I was lucky enough to attend.  

Syapse is proud to be a strategic partner in the world-class precision cancer care program that SNUH is developing. Our platform will help SNUH’s oncologists deliver more effective, personalized cancer treatments to their patients by integrating the clinical, molecular, and outcomes data needed to make the most informed treatment decisions. And we’re helping them build the program on a large scale.

The symposium brought together more than 200 people, including hospital executives from around Korea and government officials. As the first hospital system in Korea to implement an oncology precision medicine platform, SNUH executives discussed the vision for their program and the insights gained from the implementation process with Syapse.

The event was chaired by SNUH CIO Dr. Kyung Hwan Kim, who said, “The introduction of Syapse is expected to revolutionize the treatment of patients who receive next-generation sequencing.” Other SNUH executives discussed how Syapse will enable the health system to build not just big data, but smart data, that can help their treatment decisions.

And I had the opportunity to share my views on how far Syapse, and the precision medicine ecosystem more broadly, has come and where we are headed.

Before using Syapse, clinical and genomic data at SNUH were located in separate IT systems and could only be interpreted in a fragmented way — a problem faced by many health systems in the U.S. as well. Implementing Syapse gave SNUH an opportunity to rethink its data structure. Their oncologists now have a single platform to view integrated and standardized clinical and genomic data, plus treatment guidance, all at the point of care. This single platform also makes it easier for oncologists to share and discuss clinical and genomic data while maintaining patient privacy.

As Professor Koh Youngil from the Department of Hematology and Oncology at SNUH, said, “The amount of genomic data is vast, and we do not have a complete understanding about various types of genomic variations, treatment options, and outcome information for each cancer. As we share the targeted therapy data, we expect that unnecessary treatment trial and error will be greatly reduced.”

SNUH is working toward a future in which all cancer patients have access to the best precision care, and Syapse is honored to be supporting them in this mission.